FTC makes final its consent order to approve GlaxoSmithKline merger
GlaxoSmithKline plc (LSE/NYSE:GSK) today announces that, following a period of public comment, the US Federal Trade Commission (FTC) has made final its consent order to approve the merger of Glaxo Wellcome and SmithKline Beecham. The FTC vote to finalise the consent decree was 5-0.
When the FTC approved the terms of the consent decree on 18th December 2000 it stated that it would continue investigating the potential effects of the merger in the area of smoking cessation products. The FTC has voted 5-0 to close its investigation into this area.
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
Most read news
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.